Denovo Biopharma

Biotechnology ResearchCalifornia, United States11-50 Employees

Denovo Biopharma is a privately held biotechnology company based in San Diego, California, focused on advancing personalized drug development through biomarker discovery. The company operates a platform that performs de novo genomic biomarker discovery retrospectively using archived clinical samples. By identifying biomarkers associated with how patients respond to drug candidates, this approach supports designing targeted clinical trials to improve efficacy and reduce adverse effects, applicable across therapeutic areas such as oncology and neurology.

Its lead asset, liafensine, is an antidepressant candidate in Phase 3 development and has shown robust efficacy in ANK3-positive patients with treatment-resistant depression in pivotal data, along with an excellent safety profile based on data from nearly 1,500 individuals exposed. Beyond liafensine, Denovo pursues biomarker-guided strategies, including a collaboration with QIAGEN to develop a companion diagnostic for diffuse large B-cell lymphoma and a gene therapy program for recurrent high-grade glioma (DB107). A recent development: in May 2024, the company attended the ASCP 2024 Annual Meeting to present positive Phase 2b ENLIGHTEN trial data for the DGM4 biomarker-guided DB104 (liafensine) in treatment-resistant depression.

Sign up for free to view info

Email Format Employee directory